AIM ImmunoTech Files 8-K for Regulation FD Disclosure
Ticker: AIM · Form: 8-K · Filed: Jan 10, 2024 · CIK: 946644
| Field | Detail |
|---|---|
| Company | Aim Immunotech INC. (AIM) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-governance
TL;DR
**AIM ImmunoTech just dropped an 8-K for Regulation FD, keeping everyone in the loop.**
AI Summary
AIM ImmunoTech Inc. filed an 8-K on January 10, 2024, primarily to disclose information under Regulation FD. This filing indicates that the company is making certain information public, likely to ensure fair and broad dissemination to all investors. For shareholders, this means the company is adhering to transparency regulations, which can build trust and potentially stabilize stock value by preventing information asymmetry.
Why It Matters
This filing ensures all investors receive important company information simultaneously, promoting transparency and fair trading practices. It helps prevent insider trading based on non-public information.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure for Regulation FD, indicating transparency rather than a specific new risk.
Analyst Insight
Investors should review the specific content of the Regulation FD disclosure, which is not detailed in this summary 8-K, to understand what information was made public and assess its potential impact on the company's outlook or valuation.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — the registrant filing the 8-K
- January 10, 2024 (date) — the date of the report
- 001-27072 (number) — Commission File Number for AIM ImmunoTech Inc.
- 52-0845822 (number) — I.R.S. Employer Identification No. for AIM ImmunoTech Inc.
FAQ
What is the primary purpose of AIM ImmunoTech Inc.'s 8-K filing on January 10, 2024?
The primary purpose of AIM ImmunoTech Inc.'s 8-K filing on January 10, 2024, is to disclose information under Regulation FD Disclosure, as indicated in the 'ITEM INFORMATION' section of the filing.
What is AIM ImmunoTech Inc.'s Commission File Number?
AIM ImmunoTech Inc.'s Commission File Number is 001-27072, as stated in the 'FORM 8-K' section of the filing.
Where are the principal executive offices of AIM ImmunoTech Inc. located?
The principal executive offices of AIM ImmunoTech Inc. are located at 2117 SW Highway 484, Ocala, FL 34473, according to the 'FORM 8-K' section of the filing.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (352) 448-7797, as provided in the 'FORM 8-K' section of the filing.
Is AIM ImmunoTech Inc. an emerging growth company?
No, AIM ImmunoTech Inc. is not an emerging growth company, as indicated by the unchecked box next to 'Emerging growth company' in the 'FORM 8-K' section of the filing.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-01-10 08:45:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001493152-24-001905.txt ( ) — 247KB
- aim-20240110.xsd (EX-101.SCH) — 3KB
- aim-20240110_lab.xml (EX-101.LAB) — 33KB
- aim-20240110_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM IMMUNOTECH INC. January 10, 2024 By: /s/ Thomas K. Equels